TO OUR SHAREHOLDERS |
|
FRESENIUS SHARE 2011 |
|
KEY TOPICS |
|
KEY FIGURES COMPARISON |
I am pleased to report record results for sales and earnings for 2011. We increased Group sales in constant currency by 8 percent to €16.0 billion.
more...
|
|
The Fresenius share successfully defended itself against the significant price turbulences and benefited from its relative indepen- dence from the greater economy.
more...
|
|
Summary of the fiscal year
Consolidated sales increased by 3% to € 16,522 million and operating income (EBIT) grew by 6% to € 2,563 million. Earnings per share rose by 16% to € 4.73.
more...
Strategy and Goals
Our goal is to build Fresenius into a leading global provider of products and therapies for critically and chronically ill people.
more...
Employees
Well-trained and experienced employees are an important prerequisite for our company success.
more...
Outlook
With its international production and sales platform and its market-oriented products and services, the Fresenius Group is well positioned for continued growth in the coming years.
more...
|
|
Use our interactive key figures comparison. Here you can compare individual key figures and show them as graphs.
more...
|